Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-23-047251
Filing Date
2023-10-06
Accepted
2023-10-06 08:03:11
Documents
8
Period of Report
2023-12-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20010238x1_def14a.htm DEF 14A 1245264
2 logo_galectin.jpg GRAPHIC 26119
3 ny20010238x1-pc_1.jpg GRAPHIC 581100
4 ny20010238x1-pc_2.jpg GRAPHIC 528028
5 ny20010238x1_barchart01.jpg GRAPHIC 129713
6 ny20010238x1_barchart02.jpg GRAPHIC 129268
7 sig_jlewis.jpg GRAPHIC 12813
8 sig_jwcallicutt.jpg GRAPHIC 17818
  Complete submission text file 0001140361-23-047251.txt   3207147
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-31791 | Film No.: 231312639
SIC: 2834 Pharmaceutical Preparations